

Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A03E6AE9ED7EEN.html>

Date: March 2022

Pages: 171

Price: US\$ 2,000.00 (Single User License)

ID: A03E6AE9ED7EEN

Abstracts

Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 10, 11, 1, 27, 8 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Attention

Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Attention Deficit Hyperactivity Disorder (ADHD) - Overview

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development

3Z ehf

4P-Pharma SAS

ABVC BioPharma Inc

AgoneX Biopharmaceuticals Inc

Altus Formulation Inc

Amarantus Bioscience Holdings Inc

Arbor Pharmaceuticals LLC

Attentive Therapeutics Inc

Avekshan LLC

BCWorld Pharm Co Ltd

Cennerv Pharma (S) Pte Ltd

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Commave Therapeutics SA

Curemark LLC

DD Therapeutics LLC

DURECT Corp

Eli Lilly and Co

EncepHeal Therapeutics Inc

Ensysce Biosciences Inc

Highland Therapeutics Inc

Hyloris Pharmaceuticals SA
INVENT Pharmaceuticals Inc
Kashiv BioSciences LLC
KemPharm Inc
Lennham Pharmaceuticals Inc
M et P Pharma AG
Marvel Biotechnology Inc
MD Healthcare Inc
Mind Medicine MindMed Inc
Mindset Pharma Inc
NeuroNascent Inc
NLS Pharmaceuticals AG
Nobias Therapeutics Inc
NutriBand Inc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
OWP Pharmaceuticals Inc
P2D Inc
PolyCore Therapeutics LLC
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Shenox Pharmaceuticals LLC
Shionogi & Co Ltd
SK Biopharmaceuticals Co Ltd
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Taho Pharmaceuticals Ltd
Tonix Pharmaceuticals Holding Corp
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Yichang Renfu Pharmaceutical Co Ltd
Yuyu Pharma Inc
Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles
(methylphenidate hydrochloride + cyproheptadine) ER - Drug Profile
Product Description
Mechanism Of Action
(methylphenidate hydrochloride + naltrexone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action

3Z-20001 - Drug Profile

Product Description

Mechanism Of Action

3Z-20002 - Drug Profile

Product Description

Mechanism Of Action

3Z-20003 - Drug Profile

Product Description

Mechanism Of Action

3Z-20004 - Drug Profile

Product Description

Mechanism Of Action

4P-003 - Drug Profile

Product Description

Mechanism Of Action

ABV-1505 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AFI-002 - Drug Profile

Product Description

Mechanism Of Action

amfetamine ER - Drug Profile

Product Description

Mechanism Of Action

History of Events

AR-19 - Drug Profile

Product Description

Mechanism Of Action

History of Events

atomoxetine - Drug Profile

Product Description

Mechanism Of Action

atomoxetine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

BCWPE-003 - Drug Profile

Product Description

Mechanism Of Action

brilaroxazine - Drug Profile

Product Description

Mechanism Of Action

History of Events

CB-8411 - Drug Profile

Product Description

Mechanism Of Action

centanafadine SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

CM-4612 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CX-717 - Drug Profile

Product Description

Mechanism Of Action

History of Events

dexmethylphenidate hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

dextroamphetamine - Drug Profile

Product Description

Mechanism Of Action

History of Events

dextroamphetamine MR - Drug Profile

Product Description

Mechanism Of Action

History of Events

dopamine - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drug for Attention Deficit Hyperactivity Disorder and Obesity - Drug Profile

Product Description

Mechanism Of Action

Drugs for Attention Deficit Hyperactivity Disorder and Lymphatic Anomalies - Drug

Profile

Product Description

Mechanism Of Action

Drugs for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

edivoxetine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

eltoprazine - Drug Profile

Product Description

Mechanism Of Action

History of Events

histamine dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

INV-400 - Drug Profile

Product Description

Mechanism Of Action

JJC-8091 - Drug Profile

Product Description

Mechanism Of Action

History of Events

K-129 - Drug Profile

Product Description

Mechanism Of Action

KP-484 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KP-922 - Drug Profile

Product Description

Mechanism Of Action

KR-33028 - Drug Profile

Product Description

Mechanism Of Action

levofaceterane - Drug Profile

Product Description

Mechanism Of Action
History of Events
lisdexamphetamine dimesylate - Drug Profile
Product Description
Mechanism Of Action
lysergic acid diethylamide - Drug Profile
Product Description
Mechanism Of Action
History of Events
mazindol CR - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-204 - Drug Profile
Product Description
Mechanism Of Action
MDH-001 - Drug Profile
Product Description
Mechanism Of Action
MDH-204 - Drug Profile
Product Description
Mechanism Of Action
methylphenidate - Drug Profile
Product Description
Mechanism Of Action
methylphenidate ER - Drug Profile
Product Description
Mechanism Of Action
methylphenidate hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
methylphenidate hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
methylphenidate IR - Drug Profile
Product Description
Mechanism Of Action

NLS-4 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NLS-8 - Drug Profile

Product Description

Mechanism Of Action

NNI-351 - Drug Profile

Product Description

Mechanism Of Action

PCT-3012 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PD-3044 - Drug Profile

Product Description

Mechanism Of Action

PF-8001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-8026 - Drug Profile

Product Description

Mechanism Of Action

History of Events

S-874713 - Drug Profile

Product Description

Mechanism Of Action

SHX-009 - Drug Profile

Product Description

Mechanism Of Action

SKL-13865 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize ADORA for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit

Hyperactivity Disorder - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize 5-HT_{2A} for Alzheimer's Disease and Attention Deficit

Hyperactivity Disorder (ADHD) - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit SLC9A9 for ADHD - Drug Profile

Product Description

Mechanism Of Action

SPN-443 - Drug Profile

Product Description

Mechanism Of Action

SPN-446 - Drug Profile

Product Description

Mechanism Of Action

TNX-1600 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TRN-110 - Drug Profile

Product Description

Mechanism Of Action

TRN-148 - Drug Profile

Product Description

Mechanism Of Action

TRN-176 - Drug Profile

Product Description

Mechanism Of Action

vafidemstat - Drug Profile

Product Description

Mechanism Of Action

History of Events

viloxazine hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

History of Events

VU-0238429 - Drug Profile

Product Description

Mechanism Of Action

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects

Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products

Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones

Featured News & Press Releases

Feb 02, 2022: ABVC BioPharma announces principal investigator meeting for phase II part 2 ADHD clinical study

Dec 17, 2021: MindMed initiates phase 2a LSD trial for the treatment of adult ADHD

Nov 17, 2021: OWP Pharmaceuticals announces IND authorization for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of attention deficit hyperactivity disorder

Nov 05, 2021: Tris Pharma announces FDA approval of DYANAVEL XR (amphetamine) once-daily extended-release oral tablets, CII, for ADHD

Oct 27, 2021: Central IRB approved for ABV-1505 phase II part II in Taiwan sites

Sep 13, 2021: ABVC BioPharma completes site selection for ABV-1505 ADHD phase II part 2 clinical study

Sep 02, 2021: Supernus announces Qelbree sNDA for adult indication accepted for review by FDA

Sep 01, 2021: ABVC BioPharma announces new PCT filings for MDD and ADHD treatments

Aug 05, 2021: Marvel Biosciences updates market on its lead caffeine inspired asset MB-204 for neurological diseases

Jul 22, 2021: Methylphenidate - use in pregnancy

May 24, 2021: Qelbree (viloxazine extended-release capsules), a new non-controlled substance, now available for the treatment of ADHD in pediatric patients 6-17 years of age

May 05, 2021: NLS Pharmaceuticals announces patent issuance in Europe for its mazindol controlled-release formulation (mazindol CR)

Apr 22, 2021: OWP Pharmaceuticals announces patent application for the first-ever oral liquid formulation of atomoxetine hydrochloride for the treatment of Attention Deficit Hyperactivity Disorder

Apr 02, 2021: Supernus announces FDA approval of Qelbree (SPN-812) for the treatment of ADHD

Feb 22, 2021: Supernus receives FDA notice assigning early April 2021 PDUFA date for SPN-812 NDA

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)
[Expert Panel Validation](#)
[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 3Z ehf, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by ABVC BioPharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by AgoneX Biopharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Altus Formulation Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Attentive Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Avekshan LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cennerv Pharma (S) Pte Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics

LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Commave Therapeutics SA, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DD Therapeutics LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Co, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by EncepHeal Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hyloris Pharmaceuticals SA, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Kashiv BioSciences LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Lennham Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by M et P Pharma AG, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Marvel Biotechnology Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by MD Healthcare Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mind Medicine MindMed Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mindset Pharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroNascent Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharmaceuticals AG, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Nobias Therapeutics Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NutriBand Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Oryzon Genomics SA,

2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by OWP Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by PolyCore Therapeutics LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by RespireRx Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shenox Pharmaceuticals LLC, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shionogi & Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Suven Life Sciences Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tahoe Pharmaceuticals Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vallon Pharmaceuticals Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Yichang Renfu Pharmaceutical Co Ltd, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Yuyu Pharma Inc, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..1)

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..2)

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..3)

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, 2022 (Contd..4)

Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A03E6AE9ED7EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A03E6AE9ED7EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

